Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and an important dose-limiting toxicity in cancer treatment. The incidence of severe ...

The condition can increase the risk of infections. Neutropenia or low levels of neutrophils, primarily results from chemotherapy. It could also result from conditions that disrupt normal ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Neutropenia is a condition in which there are not enough neutrophils, a type of white blood cell, in the blood. Neutrophils ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

Pivotal Phase 3 4WARD clinical trial is evaluating use of oral mavorixafor as monotherapy and in combination with injectable ...

“Since the U.S. approval of G-CSF to treat severe chronic neutropenia, there has remained a significant unmet need for an optimal treatment in terms of long-term efficacy, safety, and route of ...

Risk management requirements for the atypical antipsychotic have evolved in the past 35 years to a REMS that manages the risk of severe neutropenia, which can lead to serious infections and death.

Detailed price information for X4 Pharmaceuticals Inc (XFOR-Q) from The Globe and Mail including charting and trades.